Avadel Pharmaceuticals plc (AVDL) financial statements (2022 and earlier)

Company profile

Business Address BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
DUBLIN, 15
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments157,221181,093202,843204,97573,199231,576238,554
Cash and cash equivalents50,70858,16967,14259,17271,72283,109102,174
Short-term investments106,513122,924135,701145,8031,477148,467136,380
Receivables29,09718,78919,14119,09318,95618,9466,107
Prepaid expense3,1792,7873,9834,9901,0181,4264,154
Deposits current assets  1,4181,477 1,477 
Other current assets27138249214945791294
Other undisclosed current assets2,7222,7692,82511,630169,82428,17227,910
Total current assets:192,490205,820230,702242,314263,454281,688277,019
Noncurrent Assets
Operating lease, right-of-use asset2,6522,0702,2492,4272,6042,8663,117
Property, plant and equipment285304321344359373407
Intangible assets, net (including goodwill)16,83616,83616,83616,83616,83616,83616,836
Goodwill16,83616,83616,83616,83616,83616,83616,836
Other noncurrent assets33,77738,09831,50027,71724,93922,26437,615
Other undisclosed noncurrent assets1,2259619833,3033,4453,6086,407
Total noncurrent assets:54,77558,26951,88950,62748,18345,94764,382
TOTAL ASSETS:247,265264,089282,591292,941311,637327,635341,401
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,83015,61212,6407,1219,43519,05821,053
Accounts payable7,6796,8745,1162,8242,9342,6604,879
Accrued liabilities7,1518,7387,5244,2976,50116,39815,820
Taxes payable      354
Due to related parties      1,914
Other liabilities5,2701,4713,1461,5155,2003,4313,488
Other undisclosed current liabilities900504494484474520563
Total current liabilities:21,00017,58716,2809,12015,10923,00927,018
Noncurrent Liabilities
Long-term debt and lease obligation144,104143,546143,363143,178130,050128,488126,966
Long-term debt, excluding current maturities142,397142,086141,774141,461128,210126,520124,879
Operating lease, liability1,7071,4601,5891,7171,8401,9682,087
Liabilities, other than long-term debt3,9173,9994,0684,1394,2124,9385,292
Other liabilities3,9173,9994,0684,1394,2124,9385,292
Total noncurrent liabilities:148,021147,545147,431147,317134,262133,426132,258
Total liabilities:169,021165,132163,711156,437149,371156,435159,276
Stockholders' equity
Stockholders' equity attributable to parent78,24498,957118,880136,504162,266171,200182,125
Preferred stock5555555
Common stock586586584584583582635
Treasury stock, value      (49,998)
Additional paid in capital549,349546,565544,094542,093566,916565,440615,207
Accumulated other comprehensive loss(23,940)(22,744)(22,350)(22,306)(21,051)(21,918)(22,518)
Accumulated deficit(447,756)(425,455)(403,453)(383,872)(384,187)(372,909)(361,206)
Total stockholders' equity:78,24498,957118,880136,504162,266171,200182,125
TOTAL LIABILITIES AND EQUITY:247,265264,089282,591292,941311,637327,635341,401

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues110     10,091
Cost of revenue    43 (3,285)
Cost of goods and services sold      (3,285)
Gross profit:    43 6,806
Operating expenses(23,189)(25,663)(21,936)(14,811)(14,303)(13,697)33,463
Other undisclosed operating income53      
Operating income (loss):(23,136)(25,663)(21,936)(14,811)(14,260)(13,697)40,269
Nonoperating income (expense)59548943261074213(866)
Investment income, nonoperating59548943261074213(741)
Interest and debt expense(4,154)(1,929)(1,930)(1,929)(3,308)(3,259)(3,237)
Other undisclosed income from continuing operations before equity method investments, income taxes  88783,364  
Income (loss) from continuing operations before equity method investments, income taxes:(26,695)(27,103)(23,346)(16,052)(14,130)(16,743)36,166
Other undisclosed income from continuing operations before income taxes217      
Income (loss) from continuing operations before income taxes:(26,478)(27,103)(23,346)(16,052)(14,130)(16,743)36,166
Income tax expense (benefit)4,3435,1013,7652,6072,8525,040(5,292)
Net income (loss):(22,135)(22,002)(19,581)(13,445)(11,278)(11,703)30,874
Other undisclosed net loss attributable to parent(166)      
Net income (loss) available to common stockholders, basic:(22,301)(22,002)(19,581)(13,445)(11,278)(11,703)30,874
Dilutive securities, effect on basic earnings per share      3,237
Net income (loss) available to common stockholders, diluted:(22,301)(22,002)(19,581)(13,445)(11,278)(11,703)34,111

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net income (loss):(22,135)(22,002)(19,581)(13,445)(11,278)(11,703)30,874
Other comprehensive income (loss) (394)(44)(1,255) 6001,109
Comprehensive income (loss):(22,135)(22,396)(19,625)(14,700)(11,278)(11,103)31,983
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,362)   867  
Comprehensive income (loss), net of tax, attributable to parent:(23,497)(22,396)(19,625)(14,700)(10,411)(11,103)31,983

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: